Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367668321> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4367668321 abstract "Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL." @default.
- W4367668321 created "2023-05-03" @default.
- W4367668321 creator A5005453392 @default.
- W4367668321 creator A5021363179 @default.
- W4367668321 creator A5027294123 @default.
- W4367668321 creator A5033073385 @default.
- W4367668321 creator A5037093540 @default.
- W4367668321 creator A5038208984 @default.
- W4367668321 creator A5042798628 @default.
- W4367668321 creator A5042851417 @default.
- W4367668321 creator A5053410437 @default.
- W4367668321 creator A5055086899 @default.
- W4367668321 creator A5056728544 @default.
- W4367668321 creator A5058320427 @default.
- W4367668321 creator A5058571002 @default.
- W4367668321 creator A5068452218 @default.
- W4367668321 creator A5078342005 @default.
- W4367668321 creator A5082884888 @default.
- W4367668321 creator A5085246270 @default.
- W4367668321 creator A5088169139 @default.
- W4367668321 date "2023-05-02" @default.
- W4367668321 modified "2023-10-16" @default.
- W4367668321 title "Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170" @default.
- W4367668321 doi "https://doi.org/10.1182/blood.2022019340" @default.
- W4367668321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37130017" @default.
- W4367668321 hasPublicationYear "2023" @default.
- W4367668321 type Work @default.
- W4367668321 citedByCount "5" @default.
- W4367668321 countsByYear W43676683212023 @default.
- W4367668321 crossrefType "journal-article" @default.
- W4367668321 hasAuthorship W4367668321A5005453392 @default.
- W4367668321 hasAuthorship W4367668321A5021363179 @default.
- W4367668321 hasAuthorship W4367668321A5027294123 @default.
- W4367668321 hasAuthorship W4367668321A5033073385 @default.
- W4367668321 hasAuthorship W4367668321A5037093540 @default.
- W4367668321 hasAuthorship W4367668321A5038208984 @default.
- W4367668321 hasAuthorship W4367668321A5042798628 @default.
- W4367668321 hasAuthorship W4367668321A5042851417 @default.
- W4367668321 hasAuthorship W4367668321A5053410437 @default.
- W4367668321 hasAuthorship W4367668321A5055086899 @default.
- W4367668321 hasAuthorship W4367668321A5056728544 @default.
- W4367668321 hasAuthorship W4367668321A5058320427 @default.
- W4367668321 hasAuthorship W4367668321A5058571002 @default.
- W4367668321 hasAuthorship W4367668321A5068452218 @default.
- W4367668321 hasAuthorship W4367668321A5078342005 @default.
- W4367668321 hasAuthorship W4367668321A5082884888 @default.
- W4367668321 hasAuthorship W4367668321A5085246270 @default.
- W4367668321 hasAuthorship W4367668321A5088169139 @default.
- W4367668321 hasBestOaLocation W43676683211 @default.
- W4367668321 hasConcept C121332964 @default.
- W4367668321 hasConcept C126322002 @default.
- W4367668321 hasConcept C141071460 @default.
- W4367668321 hasConcept C142424586 @default.
- W4367668321 hasConcept C197934379 @default.
- W4367668321 hasConcept C2776694085 @default.
- W4367668321 hasConcept C2777063308 @default.
- W4367668321 hasConcept C2779015954 @default.
- W4367668321 hasConcept C2779338263 @default.
- W4367668321 hasConcept C2780653079 @default.
- W4367668321 hasConcept C2911091166 @default.
- W4367668321 hasConcept C31760486 @default.
- W4367668321 hasConcept C71924100 @default.
- W4367668321 hasConcept C87355193 @default.
- W4367668321 hasConcept C90924648 @default.
- W4367668321 hasConceptScore W4367668321C121332964 @default.
- W4367668321 hasConceptScore W4367668321C126322002 @default.
- W4367668321 hasConceptScore W4367668321C141071460 @default.
- W4367668321 hasConceptScore W4367668321C142424586 @default.
- W4367668321 hasConceptScore W4367668321C197934379 @default.
- W4367668321 hasConceptScore W4367668321C2776694085 @default.
- W4367668321 hasConceptScore W4367668321C2777063308 @default.
- W4367668321 hasConceptScore W4367668321C2779015954 @default.
- W4367668321 hasConceptScore W4367668321C2779338263 @default.
- W4367668321 hasConceptScore W4367668321C2780653079 @default.
- W4367668321 hasConceptScore W4367668321C2911091166 @default.
- W4367668321 hasConceptScore W4367668321C31760486 @default.
- W4367668321 hasConceptScore W4367668321C71924100 @default.
- W4367668321 hasConceptScore W4367668321C87355193 @default.
- W4367668321 hasConceptScore W4367668321C90924648 @default.
- W4367668321 hasLocation W43676683211 @default.
- W4367668321 hasLocation W43676683212 @default.
- W4367668321 hasOpenAccess W4367668321 @default.
- W4367668321 hasPrimaryLocation W43676683211 @default.
- W4367668321 hasRelatedWork W1983005038 @default.
- W4367668321 hasRelatedWork W1994521383 @default.
- W4367668321 hasRelatedWork W2089862102 @default.
- W4367668321 hasRelatedWork W2148022022 @default.
- W4367668321 hasRelatedWork W2150129319 @default.
- W4367668321 hasRelatedWork W2156623492 @default.
- W4367668321 hasRelatedWork W2351796763 @default.
- W4367668321 hasRelatedWork W2414930736 @default.
- W4367668321 hasRelatedWork W3048121175 @default.
- W4367668321 hasRelatedWork W2515250605 @default.
- W4367668321 isParatext "false" @default.
- W4367668321 isRetracted "false" @default.
- W4367668321 workType "article" @default.